title: GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation.
abstract: Patients with non-myeloid hematologic malignancies (including Hodgkin's and non-Hodgkin's lymphomas, myeloma and acute lymphoid leukemia) or solid tumors underwent cytoreductive conditioning regimens followed by either autologous bone marrow transplantation (ABMT) (n = 343) or transplantation of peripheral blood stem cells (PBSC) with (n = 44) or without bone marrow (BM) (n = 16). In a randomized double-blind phase III multi-center trial, patients received either granulocyte-macrophage colony-stimulating factor (GM-CSF, 10 micrograms/kg/day) or placebo by daily i.v. infusion beginning 24 h after bone marrow infusion and continuing until the absolute neutrophil count (ANC) had recovered to > or = 1000/mm3, or for a maximum of 30 days. Median time to neutrophil recovery was significantly shorter in the GM-CSF group (18 vs 27 days, P < 0.001), and more GM-CSF patients had neutrophil recovery by day 30 (70 vs 48%). Median duration of hospitalization was significantly shorter in the GM-CSF group (29 vs 32 days, P = 0.02). GM-CSF significantly reduced the median time to neutrophil recovery in patients receiving bone marrow only (19 vs 27 days, P < 0.001) or PBSC with or without bone marrow (14 vs 21 days, P < 0.001). The overall incidence of adverse events was comparable in the two groups, although more patients in the GM-CSF group discontinued treatment due to adverse events (17 vs 9%, P < 0.001). No difference was noted in infection incidence or time to platelet independence. GM-CSF had no negative impact on time to relapse or long-term survival. These data indicate the positive influence of GM-CSF on neutrophil recovery and hospital stay in patients receiving ABMT for a variety of clinical indications.
authors.affiliation: Stanford University Hospital, CA, USA.
authors.forename: P
authors.initials: P
authors.lastname: Greenberg
authors.forename: R
authors.initials: R
authors.lastname: Advani
authors.forename: A
authors.initials: A
authors.lastname: Keating
authors.forename: S C
authors.initials: SC
authors.lastname: Gulati
authors.forename: S
authors.initials: S
authors.lastname: Nimer
authors.forename: R
authors.initials: R
authors.lastname: Champlin
authors.forename: C
authors.initials: C
authors.lastname: Karanes
authors.forename: N C
authors.initials: NC
authors.lastname: Gorin
authors.forename: R L
authors.initials: RL
authors.lastname: Powles
authors.forename: A
authors.initials: A
authors.lastname: Smith
authors.forename: K
authors.initials: K
authors.lastname: Lamborn
authors.forename: C
authors.initials: C
authors.lastname: Cuffie
mesh_terms: D000293:Adolescent; D000328:Adult; D004311:Double-Blind Method; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology / Q000627:therapeutic use*; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007902:Length of Stay; D015993:Life Tables; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000188:drug therapy* / Q000209:etiology; D009504:Neutrophils / Q000187:drug effects*; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D016879:Salvage Therapy; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000009:adverse effects; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor